Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy

Breast Cancer

Volumn 21, Issue 6, 2014, Pages 761-764

  Kagara, Naofumi ^a   Nakano, Yoshiaki ^a   Watanabe, Ami ^a   Inatome, Junichi ^a   Nakamura, Hidetoshi ^a   Kim, Chiwan ^a   Danno, Katsuki ^a   Taniguchi, Hirokazu ^a   Kanoh, Toshiyuki ^a   Kimura, Yutaka ^a   Ohnishi, Tadashi ^a   Tono, Takeshi ^a   Monden, Takushi ^a   Imaoka, Shingi ^a   Kagawa, Kazufumi ^a  

^a OSAKA POLICE HOSPITAL   (Japan)

Author keywords

Curative intent SBRT; Liver metastasis of breast cancer; Oligometastases

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; TAXOID;

BREAST NEOPLASMS; CASE REPORT; FEMALE; HUMAN; LIVER NEOPLASMS; MIDDLE AGED; NEOPLASM, RESIDUAL; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOSURGERY; SECONDARY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; NEOPLASM, RESIDUAL; RADIOSURGERY; TAXOIDS;

EID: 84919951323     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-011-0290-5     Document Type: Article

References (22)

1. Pivot X, Asmar L, Hortobagyi GN, Theriault R, Pastorini F, Buzdar A. A retrospective study of first indicators of breast cancer recurrence. Oncology. 2000;58:185–90.
2. Tampellini M, Berruti A, Gerbino A, Buniva T, Torta M, Gorzegno G, et al. Relationship between CA 15–3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. Br J Cancer. 1997;75:698–702.
3. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
4. Lermite E, Marzano E, Chereau E, Rouzier R, Pessaux P. Surgical resection of liver metastases from breast cancer. Surg Oncol. 2010;19:e79–84.
5. Illing R, Gillams A. Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol (R Coll Radiol). 2010;22:781–4.
6. Harrison LE, Koneru B, Baramipour P, Fisher A, Barone A, Wilson D, et al. Locoregional recurrences are frequent after radiofrequency ablation for hepatocellular carcinoma. J Am Coll Surg. 2003;197:759–64.
7. Sutherland LM, Williams JA, Padbury RT, Gotley DC, Stokes B, Maddern GJ. Radiofrequency ablation of liver tumors: a systematic review. Arch Surg. 2006;141:181–90.
8. Livraghi T, Goldberg SN, Solbiati L, Meloni F, Ierace T, Gazelle GS. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology. 2001;220:145–9.
9. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226:441–51.
10. Machi J, Uchida S, Sumida K, Limm WM, Hundahl SA, Oishi AJ, et al. Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches. J Gastrointest Surg. 2001;5:477–89.
11. Blomgren H, Lax I, Naslund I, Svanstrom R. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator. Clinical experience of the first thirty-one patients. Acta Oncol. 1995;34:861–70.
12. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2009;78:486–93.
13. Katz AW, Carey-Sampson M, Muhs AG, Milano MT, Schell MC, Okunieff P. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int J Radiat Oncol Biol Phys. 2007;67:793–8.
14. Kavanagh BD, Schefter TE, Cardenes HR, Stieber VW, Raben D, Timmerman RD, et al. Interim analysis of a prospective phase I/II trial of SBRT for liver metastases. Acta Oncol. 2006;45:848–55.
15. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27:1572–8.
16. Wulf J, Guckenberger M, Haedinger U, Oppitz U, Mueller G, Baier K, et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol. 2006;45:838–47.
17. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell MC, et al. A prospective pilot study of curative-intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions. Cancer. 2008;112:650–8.
18. Milano MT, Zhang H, Metcalfe SK, Muhs AG, Okunieff P. Oligometastatic breast cancer treated with curative-intent stereotactic body radiation therapy. Breast Cancer Res Treat. 2009;115:601–8.
19. Dawson LA, Normolle D, Balter JM, McGinn CJ, Lawrence TS, Ten Haken RK. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys. 2002;53:810–21.
20. Dawson LA, Eccles C, Craig T. Individualized image guided iso-NTCP based liver cancer SBRT. Acta Oncol. 2006;45:856–64.
21. Mendez Romero A, Zinkstok RT, Wunderink W, van Os RM, Joosten H, Seppenwoolde Y, et al. Stereotactic body radiation therapy for liver tumors: impact of daily setup corrections and day-to-day anatomic variations on dose in target and organs at risk. Int J Radiat Oncol Biol Phys. 2009;75:1201–8.
22. Dawson LA, Lawrence TS. The role of radiotherapy in the treatment of liver metastases. Cancer J. 2004;10:139–44.